Can diabetes mellitus modify the plasma concentrations of rifampicin in patients under treatment for tuberculosis?

Abstract Rifampicin is a key component of treatment for tuberculosis and its efficacy is determined by the blood levels attained after therapeutic doses. However, there is a high variability of rifampicin blood levels that is related to both the patient and the formulation used. To date, the effect of diabetes mellitus on the plasma levels of rifampicin was low exploited, which could be relevant either by the significant increase of the comorbidity worldwide as by the probable influence of diabetes on the rifampicin exposure. The study aims to evaluate whether diabetes mellitus contribute to the variation of the maximum concentration of rifampicin in patients with tuberculosis treated with a daily dose of 10 mg/kg. Rifampicin and glycated hemoglobin were measured by high-performance liquid chromatography, and blood glucose by spectrophotometry. A total of 62 male patients were included in the study, and 26 presented diabetes mellitus. Rifampicin plasma levels in 2-h plasma samples collected at day 61 ranged from 3 µg/mL to 14.2 µg/mL. Drugs levels were similar between diabetic and non-diabetic patients and were not correlated with blood glucose and glycated hemoglobin. Moreover, a high percentage of patients in both groups presented low levels of rifampicin.

Concentrations of rifampicin in pre-dose samples in patients with pulmonary tuberculosis

ABSTRACT Rifampicin is used in both phases of treatment for tuberculosis. In chronic use, the short half-life and the self-induction of metabolism can decrease the levels of the drug below the minimal inhibitory concentration. The aim of the study was to investigate whether plasma concentrations of rifampicin are sustained above 0.5 µg/mL in patients with tuberculosis using 600 mg/day. Rifampicin was measured in plasma by high-performance liquid chromatography and a sputum smear microscopy was performed in all days of the study. A total of 44 male patients completed the study. On days 31, 61 and 91, the mean plasma concentrations of rifampicin were 0.6 (0.5) µg/mL, 0.55 (0.5) µg/mL and 0.46 (0.4) µg/mL. There was a high variation of rifampicin levels leading to a high percentage of samples with concentrations below 0.5 µg/mL. There was no significant association between the frequency of samples with drug levels below 0.5 µg/mL with the conversion of the sputum microscopy. These data suggest that pre-doses samples offer limited information on the exposure of M. tuberculosis to rifampicin.

Validación de un método de cromatografía líquida para la determinación de rifampicina en plasma humano / Validation of a liquid chromatography method for rifampicin determination in human plasma

Objetivos: Validar un método de cromatografía líquida de alta resolución (HPLC) para la determinación de rifampicina (RFP) en plasma humano. Materiales y métodos. Se desarrolló un método HPLC para la determinación de RFP en plasma. La separación fue realizada por cromatografía de fase reversa con una columna C18 y una fase móvil compuesta por una mezcla de acetonitrilo y solución amortiguadora de fosfato de potasio monobásico 0,05 M (38:62 v/v) a 335 nm. En el cual se empleó como estándar interno rifampicina quinona (RFP-QN). Resultados. Los tiempos de retención de RFP y RFP-QN fueron 7,81 y 12,26 minutos, respectivamente. El ensayo fue lineal de 0,5 a 250 ug/mL Los parámetros evaluados de precisión, exactitud, selectividad, linealidad, recuperación cumplieron con lo establecido en las guías internacionales de validación de métodos bioanalíticos. Conclusiones. El método HPLC desarrollado es simple, específico, sensible, selectivo y lineal para un amplio rango de concentraciones de RFP en plasma.

Objectives: To validate the high-performance liquid chromatography method (HPLC) for rifampicin (RFP) determination in human plasma. Materials and methods. A HPLC method for RFP determination in plasma was developed. The separation was performed by reversed-phase chromatography with C18 column and a mobile phase composed of a mixture of acetonitrile and monobasic potassium phosphate buffer solution 0.05 M (38:62 v/v) at 335 nm in which standard rifampicin quinone (RFP-QN) was used. Results. The retention times of RFP and RFP-QN were 7.81 and 12.26 minutes, respectively. The trial was linear from 0.5 to 250 ug/mL. The evaluated parameters of precision, accuracy, selectivity, linearity, and recovery complied with the established international standards for validation of bioanalytical methods. Conclusions. The developed HPLC method is simple, specific, sensitive, selective and linear for a wide range of RFP concentrations in plasma.

Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis

Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide were studied in healthy controls and patients with active pulmonary tuberculosis. A case-control study of 29 controls and 30 cases attending at the Health Center, July, 2004 to December, 2005 was conducted. The body mass index was significantly reduced in cases compared to controls (p < 0.001). The intestinal paracellular transport of lactulose was significantly (p = 0.019) reduced in cases compared to controls. The transcellular transport of mannitol and the lactulose:mannitol ratio were not significantly (p = 0.0698) reduced in cases compared to controls. Low serum concentrations of rifampin, isoniazid and pyrazinamide were observed in 81 percent (48/59), 92 percent (54/59) and 28 percent (12/59), respectively, in all individuals. The results demonstrated a marked decrease on intestinal paracellular transport in patients with active pulmonary tuberculosis and reduced serum concentrations of rifampin and isoniazid in both groups.

Correlação entre dose/concentração plasmática e avaliação de alterações hepáticas e renais em ratos Wistar tratados com o esquema ROM / Correlation between dose/plasma concentration and assessment of hepatic and renal changes in Wistar rats treated with the ROM scheme

A hanseníase, doença crônica, granulomatosa, infecto-contagiosa, transmitida pelo Mycobacterium leprae, ainda se mantém prevalente nos dias atuais, principalmente em países subdesenvolvidos e a sua forma paucibacilar com lesão única, vem sendo tratada através da administração de rifampicina (600mg), ofloxacina (400mg) e minociclina (100mg), em dose única (esquema ROM). Assim, o objetivo deste trabalho foi investigar a correlação dose/concentração plasmática versus alterações bioquímicas na administração da rifampicina, ofloxacina e minociclina a ratos machos Wistar, em regime de dose única em mono e politerapia. Concluímos que a rifampicina e a ofloxacina sofreram um aumento na concentração plasmática quando administrados em politerapia, enquanto que a minociclina sofreu uma redução, provavelmente por interferências na biotransformação e excreção. Constatamos através das análises bioquímicas que a rifampicina provavelmente é a responsável por alterações hepáticas e renais, e que as interações medicamentosas envolvendo o fármaco exigem estudos individualizados principalmente quando o fármaco é usado associado a ofloxacina e minociclina.

Serum and cerebrospinal fluid concentrations of rifampicin at two dose levels in children with tuberculous meningitis.

Twenty patients of tuberculous meningitis (TBM) in age group of 6 months to 10 years included in the study were divided into two groups of 10 patients each. Rifampicin was administered in dosage of 10 mg and 7.5 mg/kg bw to each patient of groups I and II respectively. Drug concentrations in serum and CSF of these patients were measured by a microbiological tube dilution method using a strain of Sarcina lutea. In group I mean serum and CSF concentration was 3.84 micrograms/ml and 0.178 microgram/ml respectively, while in group II it was 2.16 micrograms/ml and 0.206 microgram/ml respectively. These concentrations were many times higher than the MIC against Mycobacterium tuberculosis. Mean percentage penetration of rifampicin in CSF was 5 and 10% in group I and II respectively. We recommend similar studies in large number of children before advocating the therapy with low dose of rifampicin in TBM.

Chronopharmacokinetics of rifampicin.

Chronopharmacokinetics of rifampicin was studied in four healthy adult male human volunteers after drug (2.0 g) ingestion at 6.00, 12.00, 18.00 and 24.00 hr. The absorption rate constant was found to be lower and the time to reach peak concentration was longer after drug administration at 24.00 hr than at other dosing times. A second peak was observed in all individual volunteers between 6-12 hr after drug dosing at 24.00 hr. This may be due to the influence of biliary rhythms on the disposition kinetics of rifampicin.

Interaccion farmacocinetica entre Ketoconazol Isoniacida y Rifampicina / Pharmacokinetic interaction of ketoconazole, Isoniacid and Rifampicin

A 8 enfermos tuberculosos, varones, entre 20 y 60 años de edad, se les dio Isoniacida, 5 mg/Kg, y Ketoconazol, 200 mg, primero uno por vez y luego, asociados y se midió la concentración plasmática de las drogas a las horas 0,2 y de la toma. Isoniacida se midió por espectrofotometría y de Ketoconazol, por método microbiológico con Candida albicans como cepa testigo. Cuando se dieron ambas drogas asociadas se comprobó un marcado descensio de la concentración de Ketoconazol pero no hubo modificaciónes en la concentración de isoniacida. Un estudio análogo se efectuócon 11 pacientes tuberculosos a quienes se les dio Rifampicina, 10 mg/Kg, y Ketoconazol mg. Las concentraciones de ambas drogas se midieron a las mismsas horas. La rifampicina se midió por cromatografía líquida de alta presión. Al recibir las drogas asociadas se comprobó un marcado descenso en las concentraciones plasmáticas tanto para la Rifampicina como para el ketoconazol. La investigación de una probable interacción quimica entre Isoniacida y Ketoconazol por un lado y entre Rifampicina y Ketoconazol, por otro lado, dio resultados negativos. Se concluye que existe una marcada interacción farmacocinética del Ketoconazol con Isoniacida y Rifampicina, hecho que debe ser tenido en cuenta si se deben administrar tratamiento antimicótico y antiinfecciosos simultáneos

Microbiological assay versus spectrophotometry for determination of rifampicin in urine.

A comparative study on the microbiological and spectrophotometric methods for estimation of rifampicin in urine was carried out in 15 individuals. The urinary levels of rifampicin were determined on 2nd, 8th and 15th days at 3 hour, 6 hour and 24 hour samples by the above methods after administration of 600 mg rifampicin. The results suggest that the microbiological assay is more sensitive than spectrophotometric method. The difference was highly significant in all the cases by paired t-test. Incidentally it was also noticed that urinary excretion of rifampicin was comparatively more on 15th day.